Citius Pharmaceuticals Inc Stock News

Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures CRANFORD, N.J., Nov. 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CT...

CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial order...

$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company ...

$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biophar...

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑own...

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the commercial...

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients 20.5 months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21) Responses were observed in patients previousl...